دورية أكاديمية
Proteomic analysis of the effect of hemin in breast cancer.
| العنوان: | Proteomic analysis of the effect of hemin in breast cancer. |
|---|---|
| المؤلفون: | Coló GP; Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB-UNS-CONICET), Bahía Blanca, Argentina., Schweitzer K; Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB-UNS-CONICET), Bahía Blanca, Argentina., Oresti GM; Laboratorio de Bioquímica de Lípidos, Departamento de Biología, Bioquímica y Farmacia (UNS), Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB-UNS-CONICET), Argentina, 8000, Bahía Blanca, CP, Argentina., Alonso EG; Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB-UNS-CONICET), Bahía Blanca, Argentina., Chávez LF; Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB-UNS-CONICET), Bahía Blanca, Argentina., Mascaró M; Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB-UNS-CONICET), Bahía Blanca, Argentina., Giorgi G; Laboratorio de Fisiología Humana, Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, Bahía Blanca, Argentina., Curino AC; Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB-UNS-CONICET), Bahía Blanca, Argentina., Facchinetti MM; Laboratorio de Biología del Cáncer, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB-UNS-CONICET), Bahía Blanca, Argentina. facchinm@criba.edu.ar.; Laboratorio de Fisiología Humana, Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, Bahía Blanca, Argentina. facchinm@criba.edu.ar. |
| المصدر: | Scientific reports [Sci Rep] 2023 Jun 21; Vol. 13 (1), pp. 10091. Date of Electronic Publication: 2023 Jun 21. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Nature Publishing Group, copyright 2011- |
| مواضيع طبية MeSH: | Hemin*/pharmacology , Breast Neoplasms*, Humans ; Female ; Heme Oxygenase-1/metabolism ; Proteomics ; Heme Oxygenase (Decyclizing)/metabolism ; Heme/metabolism ; Iron/metabolism |
| مستخلص: | Heme, an iron-containing prosthetic group found in many proteins, carries out diverse biological functions such as electron transfer, oxygen storage and enzymatic reactions. Hemin, the oxidised form of heme, is used to treat porphyria and also to activate heme-oxygenase (HO) which catalyses the rate-limiting step in heme degradation. Our group has previously demonstrated that hemin displays antitumor activity in breast cancer (BC). The aim of this work has been to study the effect of hemin on protein expression modifications in a BC cell line to gain insight into the molecular mechanisms of hemin antitumor activity. For this purpose, we carried out proteome analysis by Mass Spectrometry (MS) which showed that 1309 proteins were significantly increased in hemin-treated cells, including HO-1 and the proteases that regulate HO-1 function, and 921 proteins were significantly decreased. Furthermore, the MS-data analysis showed that hemin regulates the expression of heme- and iron-related proteins, adhesion and cytoskeletal proteins, cancer signal transduction proteins and enzymes involved in lipid metabolism. By biochemical and cellular studies, we further corroborated the most relevant in-silico results. Altogether, these results show the multiple physiological effects that hemin treatment displays in BC and demonstrate its potential as anticancer agent. (© 2023. The Author(s).) |
| References: | FASEB J. 1988 Jul;2(10):2557-68. (PMID: 3290025) J Biol Chem. 2009 Dec 25;284(52):36302-36311. (PMID: 19850937) Blood. 2012 Nov 29;120(23):4496-504. (PMID: 22791288) Curr Opin Cell Biol. 1998 Feb;10(1):123-30. (PMID: 9484604) J Cell Sci. 2016 Apr 1;129(7):1391-403. (PMID: 26872785) FASEB J. 2020 Jun;34(6):8028-8043. (PMID: 32301543) J Cell Sci. 2001 Aug;114(Pt 15):2713-22. (PMID: 11683406) Pathol Res Pract. 2020 Sep;216(9):153068. (PMID: 32825941) J Biol Chem. 2007 Jul 13;282(28):20621-33. (PMID: 17430897) Exp Cell Res. 2022 Jan 1;410(1):112946. (PMID: 34826424) Nat Methods. 2016 Sep;13(9):731-40. (PMID: 27348712) Front Pharmacol. 2022 Feb 28;13:791272. (PMID: 35295334) Trends Cell Biol. 2005 Feb;15(2):76-83. (PMID: 15695094) Br J Pharmacol. 2015 Sep;172(17):4228-37. (PMID: 26040571) Clin Cancer Res. 2017 Sep 1;23(17):5135-5148. (PMID: 28512172) Chem Rev. 2014 Apr 9;114(7):3919-62. (PMID: 24400737) J Cell Sci. 1999 Dec;112 ( Pt 24):4615-25. (PMID: 10574710) Mol Cancer Res. 2009 Nov;7(11):1745-55. (PMID: 19903769) Int J Mol Sci. 2022 May 20;23(10):. (PMID: 35628518) Trends Cell Biol. 2008 May;18(5):210-9. (PMID: 18394899) Front Pharmacol. 2012 May 04;3:77. (PMID: 22586395) Oncotarget. 2016 Oct 18;7(42):69075-69086. (PMID: 27626166) J Biol Chem. 1969 Dec 10;244(23):6388-94. (PMID: 4390967) Biochem J. 2015 Mar 1;466(2):401-13. (PMID: 25697096) Oncogene. 2015 Apr 30;34(18):2360-70. (PMID: 24931165) Nat Cell Biol. 2002 Apr;4(4):294-301. (PMID: 11912491) Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9529-34. (PMID: 15976019) Exp Mol Pathol. 2014 Dec;97(3):321-31. (PMID: 25236576) Biochim Biophys Acta Mol Basis Dis. 2023 Mar;1869(3):166621. (PMID: 36539019) Breast Cancer (Auckl). 2015 Sep 27;9(Suppl 2):17-34. (PMID: 26462242) Biomedicines. 2021 Nov 09;9(11):. (PMID: 34829880) Exp Mol Pathol. 2012 Oct;93(2):237-45. (PMID: 22580187) Nat Rev Cancer. 2018 Sep;18(9):533-548. (PMID: 30002479) Int J Environ Res Public Health. 2021 Mar 30;18(7):. (PMID: 33808259) ACS Chem Biol. 2018 Aug 17;13(8):1996-2002. (PMID: 29869870) Science. 1998 Jan 23;279(5350):509-14. (PMID: 9438836) PLoS One. 2009 Nov 13;4(11):e7830. (PMID: 19915675) Cancer Res. 2002 Jan 15;62(2):497-505. (PMID: 11809701) Front Oncol. 2020 Jan 15;9:1540. (PMID: 32010627) Antioxidants (Basel). 2021 Jan 11;10(1):. (PMID: 33440611) Nat Rev Mol Cell Biol. 2016 Aug;17(8):496-510. (PMID: 27301673) Mediators Inflamm. 2010;2010:359732. (PMID: 20508722) Mol Biol Cell. 2012 Jul;23(13):2583-92. (PMID: 22593214) Oncogene. 2019 Mar;38(10):1688-1701. (PMID: 30348988) Int J Oncol. 1997 Sep;11(3):489-96. (PMID: 21528237) Nat Rev Mol Cell Biol. 2004 Nov;5(11):920-31. (PMID: 15520811) Am J Cancer Res. 2021 Dec 15;11(12):5856-5863. (PMID: 35018229) Antioxid Redox Signal. 2019 Jun 20;30(18):2030-2049. (PMID: 30484334) Nucleic Acids Res. 2000 Jan 1;28(1):27-30. (PMID: 10592173) J Biol Chem. 1995 Aug 4;270(31):18388-95. (PMID: 7629163) Arch Biochem Biophys. 2019 Sep 30;673:108073. (PMID: 31425676) PET Clin. 2018 Jul;13(3):325-338. (PMID: 30100073) PLoS One. 2013 Aug 01;8(8):e71542. (PMID: 23936516) Sci Signal. 2014 Sep 23;7(344):re8. (PMID: 25249658) |
| المشرفين على المادة: | 743LRP9S7N (Hemin) EC 1.14.14.18 (Heme Oxygenase-1) EC 1.14.14.18 (Heme Oxygenase (Decyclizing)) 42VZT0U6YR (Heme) E1UOL152H7 (Iron) |
| تواريخ الأحداث: | Date Created: 20230621 Date Completed: 20230623 Latest Revision: 20230701 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10284804 |
| DOI: | 10.1038/s41598-023-35125-4 |
| PMID: | 37344532 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2045-2322 |
|---|---|
| DOI: | 10.1038/s41598-023-35125-4 |